30/04/21
CM Life Sciences highlights Avrion Therapeutics as one of five exciting neurology companies
Read More…19/04/21
Attend for free online and hear more about Avrion from CEO Maximilien Murone during EPFLs Startup Champions Night.
Read More…31/03/21
Bilan magazine, the influential Swiss and international business and economy publication, has selected Avrion Therapeutics as one the
six best start-ups in which to invest in 2021 from a comparison of 270 new Swiss companies.
Read More… 19/01/21
Avrion CSO Dr. Bernard Schneider authors a new study demonstrating the potent effects of specifically targeting disease causing SOD1 by gene therapy in the astrocytes of a mouse model of the motor neuron disease ALS. The study shows that specifically targeting SOD1 in this cell type enables plasticity and re-innervation, increasing the number and activity of neuromuscular junctions, the essential connections between motor neurons and muscles, thereby allowing the preservation of muscle function. The data from this study have been incorporated in the design of AVR-001, Avrion's first gene therapy product aimed to treat ALS.
Read More… 13/01/21
Avrion Therapeutics AG elects Dr. Gael Hedou, founder and former CEO of Relief Therapeutics Holding AG, as new Chairman of the Board of Directors.
Read More…16/12/20
Avrion CEO Maximilien Murone discusses Avrion and his management philosophy as part of the Sejelas Founders-CEO interview series.
Read More…14/09/20
Avrion was part of the Swiss representation at Bio Europe, Europe’s largest platform for companies in the biotech and pharma sectors to meet and forge partnerships.
Read More…17/08/20
Avrion Therapeutics AG (
AvrionTx) was incorporated in Basel, the hub of the Swiss pharmaceutical industry, on August 17th 2020. The AvrionTx motto is "
Correct for Life" and we aspire to bring long-term solutions for neurodegenerative diseases through precision gene therapy.
Read More…